Actinogen Medical Toekomstige groei
Future criteriumcontroles 2/6
Actinogen Medical's earnings are forecast to decline at 22.1% per annum while its annual revenue is expected to grow at 20% per year. EPS is expected to decline by 0.01% per annum.
Belangrijke informatie
-22.1%
Groei van de winst
-0.009%
Groei van de winst per aandeel
Biotechs winstgroei | 15.2% |
Inkomstengroei | 20.0% |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Low |
Laatst bijgewerkt | 31 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?
Apr 30Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?
Nov 16Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?
Aug 02We Think Actinogen Medical (ASX:ACW) Can Afford To Drive Business Growth
Apr 12We're Hopeful That Actinogen Medical (ASX:ACW) Will Use Its Cash Wisely
Nov 28Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation
Aug 09Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation
Apr 07We're Not Worried About Actinogen Medical's (ASX:ACW) Cash Burn
Oct 24Actinogen Medical (ASX:ACW) Is In A Strong Position To Grow Its Business
Jul 11We're Interested To See How Actinogen Medical (ASX:ACW) Uses Its Cash Hoard To Grow
Mar 27How Does Actinogen Medical's (ASX:ACW) CEO Pay Compare With Company Performance?
Jan 07Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
6/30/2026 | 14 | -20 | -13 | N/A | 1 |
6/30/2025 | 7 | -12 | -9 | N/A | 1 |
6/30/2024 | 10 | -13 | -17 | -17 | N/A |
3/31/2024 | 7 | -14 | -15 | -15 | N/A |
12/31/2023 | 5 | -15 | -13 | -13 | N/A |
9/30/2023 | 5 | -13 | -11 | -11 | N/A |
6/30/2023 | 5 | -11 | -9 | -9 | N/A |
3/31/2023 | 5 | -11 | -9 | -9 | N/A |
12/31/2022 | 5 | -11 | -9 | -9 | N/A |
9/30/2022 | 4 | -10 | -9 | -9 | N/A |
6/30/2022 | 4 | -9 | -10 | -10 | N/A |
3/31/2022 | 3 | -8 | -8 | -8 | N/A |
12/31/2021 | 2 | -7 | -6 | -6 | N/A |
9/30/2021 | 2 | -6 | -4 | -4 | N/A |
6/30/2021 | 2 | -4 | -2 | -2 | N/A |
3/31/2021 | 2 | -4 | -2 | -2 | N/A |
12/31/2020 | 3 | -4 | -2 | -2 | N/A |
9/30/2020 | 3 | -4 | -3 | -3 | N/A |
6/30/2020 | 4 | -5 | -3 | -3 | N/A |
3/31/2020 | 5 | -6 | -5 | -5 | N/A |
12/31/2019 | 6 | -7 | -7 | -7 | N/A |
9/30/2019 | 5 | -8 | -9 | -9 | N/A |
6/30/2019 | 5 | -10 | -10 | -10 | N/A |
3/31/2019 | 4 | -10 | -10 | -10 | N/A |
12/31/2018 | 3 | -10 | -9 | -9 | N/A |
9/30/2018 | 3 | -8 | -8 | -8 | N/A |
6/30/2018 | 3 | -6 | -8 | -8 | N/A |
3/31/2018 | 2 | -6 | N/A | -6 | N/A |
12/31/2017 | 2 | -5 | N/A | -4 | N/A |
9/30/2017 | 1 | -4 | N/A | -3 | N/A |
6/30/2017 | 1 | -3 | N/A | -1 | N/A |
3/31/2017 | 2 | -4 | N/A | -2 | N/A |
12/31/2016 | 3 | -4 | N/A | -2 | N/A |
9/30/2016 | 3 | -4 | N/A | -4 | N/A |
6/30/2016 | 4 | -4 | N/A | -5 | N/A |
3/31/2016 | 3 | -5 | N/A | -5 | N/A |
12/31/2015 | 1 | -5 | N/A | -5 | N/A |
9/30/2015 | 1 | -5 | N/A | -4 | N/A |
6/30/2015 | 0 | -5 | N/A | -4 | N/A |
3/31/2015 | 0 | -3 | N/A | -2 | N/A |
12/31/2014 | 0 | -2 | N/A | -1 | N/A |
9/30/2014 | 0 | -1 | N/A | -1 | N/A |
6/30/2014 | 0 | 0 | N/A | 0 | N/A |
3/31/2014 | 0 | 0 | N/A | 0 | N/A |
12/31/2013 | 0 | 0 | N/A | 0 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: ACW is forecast to remain unprofitable over the next 3 years.
Winst versus markt: ACW is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: ACW is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: ACW's revenue (20% per year) is forecast to grow faster than the Australian market (5.7% per year).
Hoge groei-inkomsten: ACW's revenue (20% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if ACW's Return on Equity is forecast to be high in 3 years time